Mass Balance Sends Self-Running Lab to Orbit on SpaceX
.png)
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Mass Balance launched a grapefruit-sized apparatus containing chemicals, sensors, and control elements on a SpaceX transporter Tuesday morning, housed in a 10-centimeter pod built by Austrian firm Tumbleweed, to orbit Earth for a couple of months.
- Toby Call, Mass Balance's cofounder and CEO, said the platform aims to image disordered proteins—responsible for Alzheimer's, Parkinson's, and some cancers—under microgravity, where the absence of convection and sedimentation produces higher-quality data unobtainable on Earth.
- Call plans to use the space-generated protein data to train an AI model adapter that fills gaps left by systems like Google's AlphaFold, which currently cannot predict how disordered proteins behave or respond to medicines; revenue will come from the model, data licensing, and data access.
- Tuesday's mission is a systems test: an industrial biocatalyst will break down another chemical compound while onboard light-based sensors confirm the reaction occurs as planned, validating the autonomous operating system before protein experiments begin.
- Unlike competitors BioOrbit (UK, which launched in May growing ultra-pure crystals for injectable cancer drugs) and Varda Space Industries (US, processing pharmaceuticals in microgravity), Mass Balance will not attempt to return its hardware to Earth, sidestepping the re-entry heat and stress engineering challenges.
- Call framed the long-term vision: "When you take away gravity, a lot of weird and wonderful things happen... the goal is really to make space boring, reliable, and just another research environment."
Why it matters: Disordered proteins are a blind spot for AI drug-discovery tools like AlphaFold, and Mass Balance is betting that microgravity data—free of convection and sedimentation—can fill that gap. If the autonomous system works, it creates a new data pipeline for pharma and AI model training that competitors are racing toward, with BioOrbit and Varda already pursuing adjacent microgravity bioprocessing approaches.
